Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RU-79115 (Aventis Pharma).

S C Annedi1, L P Kotra

  • 1Faculty of Pharmacy, University of Toronto, ON, Canada.

Current Opinion in Investigational Drugs (London, England : 2000)
|September 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptidyl Arginine Deiminases and Neurodegenerative Diseases.

Current medicinal chemistry·2015
Same author

Inhibition of orotidine 5'-monophosphate decarboxylase and its therapeutic potential.

Mini reviews in medicinal chemistry·2008
Same author

Insight into the complex and dynamic process of activation of matrix metalloproteinases.

Journal of the American Chemical Society·2001
Same author

X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. comparison with the latent and active forms of the enzyme.

The Journal of biological chemistry·2001
Same author

Substrate hydrolysis by matrix metalloproteinase-9.

The Journal of biological chemistry·2001
Same author

Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa.

Structure (London, England : 1993)·2001
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Novel coumarin DNA gyrase B inhibitors, like RU-79115, show potent antibacterial activity, especially against resistant Gram-positive bacteria. These compounds offer a promising new avenue for treating challenging bacterial infections.

Area of Science:

  • Medicinal Chemistry
  • Microbiology
  • Pharmacology

Background:

  • Bacterial infections pose a significant threat, with rising resistance to existing antibiotics.
  • Novel therapeutic targets are crucial for developing new antibacterial agents.
  • DNA gyrase B is a validated target for antibacterial drug development.

Purpose of the Study:

  • To investigate novel coumarin derivatives as potential antibacterial agents.
  • To evaluate the in vitro and in vivo efficacy of these compounds, particularly RU-79115.
  • To assess their activity against resistant bacterial strains.

Main Methods:

  • Synthesis and chemical modification of coumarin-based compounds.
  • In vitro assays to determine inhibitory activity against DNA gyrase B and antibacterial spectrum.

Related Experiment Videos

  • In vivo studies to evaluate safety and pharmacokinetic profiles.

    • Main Results:

    • Coumarin derivatives, including RU-79115, demonstrated potent inhibition of DNA gyrase B and significant in vitro antibacterial activity.
    • Compounds showed notable efficacy against vancomycin- and teicoplanin-resistant enterococci and novobiocin-resistant strains.
    • RU-79115 exhibited favorable activity against Gram-positive bacteria, including resistant staphylococci, outperforming existing antibiotics in some cases.
    • In vivo studies indicated a favorable safety and pharmacokinetic profile for RU-79115.

    Conclusions:

    • Novel coumarin derivatives, exemplified by RU-79115, represent a promising class of antibacterial agents.
    • These compounds are effective against challenging resistant bacterial pathogens.
    • RU-79115 warrants further development as a potential therapeutic for bacterial infections.